IBDEI31H ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,48529,1,3,0)
 ;;=3^Muscle Wasting/Atrophy,Unspec Site NEC
 ;;^UTILITY(U,$J,358.3,48529,1,4,0)
 ;;=4^M62.50
 ;;^UTILITY(U,$J,358.3,48529,2)
 ;;=^5012655
 ;;^UTILITY(U,$J,358.3,48530,0)
 ;;=M62.81^^185^2423^89
 ;;^UTILITY(U,$J,358.3,48530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48530,1,3,0)
 ;;=3^Muscle Weakness,Generalized
 ;;^UTILITY(U,$J,358.3,48530,1,4,0)
 ;;=4^M62.81
 ;;^UTILITY(U,$J,358.3,48530,2)
 ;;=^332922
 ;;^UTILITY(U,$J,358.3,48531,0)
 ;;=M61.9^^185^2423^90
 ;;^UTILITY(U,$J,358.3,48531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48531,1,3,0)
 ;;=3^Muscle,Calcification/Ossification,Unspec
 ;;^UTILITY(U,$J,358.3,48531,1,4,0)
 ;;=4^M61.9
 ;;^UTILITY(U,$J,358.3,48531,2)
 ;;=^5012561
 ;;^UTILITY(U,$J,358.3,48532,0)
 ;;=M62.40^^185^2423^91
 ;;^UTILITY(U,$J,358.3,48532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48532,1,3,0)
 ;;=3^Muscle,Contracture,Unspec Site
 ;;^UTILITY(U,$J,358.3,48532,1,4,0)
 ;;=4^M62.40
 ;;^UTILITY(U,$J,358.3,48532,2)
 ;;=^5012631
 ;;^UTILITY(U,$J,358.3,48533,0)
 ;;=M62.9^^185^2423^84
 ;;^UTILITY(U,$J,358.3,48533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48533,1,3,0)
 ;;=3^Muscle Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,48533,1,4,0)
 ;;=4^M62.9
 ;;^UTILITY(U,$J,358.3,48533,2)
 ;;=^5012684
 ;;^UTILITY(U,$J,358.3,48534,0)
 ;;=M62.20^^185^2423^92
 ;;^UTILITY(U,$J,358.3,48534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48534,1,3,0)
 ;;=3^Muscle,Nontraumatic Ischemic Infarction,Unspec Site
 ;;^UTILITY(U,$J,358.3,48534,1,4,0)
 ;;=4^M62.20
 ;;^UTILITY(U,$J,358.3,48534,2)
 ;;=^5012607
 ;;^UTILITY(U,$J,358.3,48535,0)
 ;;=G72.1^^185^2423^94
 ;;^UTILITY(U,$J,358.3,48535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48535,1,3,0)
 ;;=3^Myopathy,Alcoholic
 ;;^UTILITY(U,$J,358.3,48535,1,4,0)
 ;;=4^G72.1
 ;;^UTILITY(U,$J,358.3,48535,2)
 ;;=^5004096
 ;;^UTILITY(U,$J,358.3,48536,0)
 ;;=G72.81^^185^2423^95
 ;;^UTILITY(U,$J,358.3,48536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48536,1,3,0)
 ;;=3^Myopathy,Critical Illness
 ;;^UTILITY(U,$J,358.3,48536,1,4,0)
 ;;=4^G72.81
 ;;^UTILITY(U,$J,358.3,48536,2)
 ;;=^328484
 ;;^UTILITY(U,$J,358.3,48537,0)
 ;;=G72.0^^185^2423^96
 ;;^UTILITY(U,$J,358.3,48537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48537,1,3,0)
 ;;=3^Myopathy,Drug-Induced
 ;;^UTILITY(U,$J,358.3,48537,1,4,0)
 ;;=4^G72.0
 ;;^UTILITY(U,$J,358.3,48537,2)
 ;;=^5004095
 ;;^UTILITY(U,$J,358.3,48538,0)
 ;;=G72.41^^185^2423^97
 ;;^UTILITY(U,$J,358.3,48538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48538,1,3,0)
 ;;=3^Myopathy,Inclusion Body Myositis
 ;;^UTILITY(U,$J,358.3,48538,1,4,0)
 ;;=4^G72.41
 ;;^UTILITY(U,$J,358.3,48538,2)
 ;;=^5004098
 ;;^UTILITY(U,$J,358.3,48539,0)
 ;;=G72.49^^185^2423^98
 ;;^UTILITY(U,$J,358.3,48539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48539,1,3,0)
 ;;=3^Myopathy,Inflammatory/Immune NEC
 ;;^UTILITY(U,$J,358.3,48539,1,4,0)
 ;;=4^G72.49
 ;;^UTILITY(U,$J,358.3,48539,2)
 ;;=^5004099
 ;;^UTILITY(U,$J,358.3,48540,0)
 ;;=G72.2^^185^2423^99
 ;;^UTILITY(U,$J,358.3,48540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48540,1,3,0)
 ;;=3^Myopathy,Other Toxic Agents
 ;;^UTILITY(U,$J,358.3,48540,1,4,0)
 ;;=4^G72.2
 ;;^UTILITY(U,$J,358.3,48540,2)
 ;;=^5004097
 ;;^UTILITY(U,$J,358.3,48541,0)
 ;;=G72.3^^185^2423^100
 ;;^UTILITY(U,$J,358.3,48541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48541,1,3,0)
 ;;=3^Myopathy,Periodic Paralysis
 ;;^UTILITY(U,$J,358.3,48541,1,4,0)
 ;;=4^G72.3
